Here, we analyzed nine tumor markers (CA19‐9, AFP, PSA, CEA, CA125, CYFRA, CA15‐3, SCC antigen, and NCC‐ST439) in 119 patients with pancreatic cancer and 49 with hepatocellular carcinoma, alongside 590 healthy controls. This evidence concerns the gene CEACAM5 and pancreatic neoplasm.